Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study
Where Today's News Shapes Tomorrow
